122 related articles for article (PubMed ID: 11593338)
1. Highlights of the Second International Symposium on Genetic Anticancer Agents.
Gerritsen WR; Krul MR
Cancer Gene Ther; 2001 Sep; 8(9):678-80. PubMed ID: 11593338
[No Abstract] [Full Text] [Related]
2. Progress in cancer gene therapy.
Curiel DT; Gerritsen WR; Krul MR
Cancer Gene Ther; 2000 Aug; 7(8):1197-9. PubMed ID: 10975681
[TBL] [Abstract][Full Text] [Related]
3. 3rd international symposium on genetic anticancer agents.
Wysocki PJ; Mackiewicz-Wysocka M
Expert Opin Biol Ther; 2002 Jun; 2(5):565-8. PubMed ID: 12079492
[TBL] [Abstract][Full Text] [Related]
4. Cytochrome P450 1B1: a novel anticancer therapeutic target.
McFadyen MC; Murray GI
Future Oncol; 2005 Apr; 1(2):259-63. PubMed ID: 16555997
[TBL] [Abstract][Full Text] [Related]
5. Cancer cells under the fire of combined therapies.
Paillard F
Hum Gene Ther; 1998 Jun; 9(9):1259-60. PubMed ID: 9650610
[No Abstract] [Full Text] [Related]
6. Mechanisms and future directions for angiogenesis-based cancer therapies.
Scappaticci FA
J Clin Oncol; 2002 Sep; 20(18):3906-27. PubMed ID: 12228212
[TBL] [Abstract][Full Text] [Related]
7. Emerging new anticancer therapies in 2013.
Gomez-Roca C; Delord JP
Curr Opin Oncol; 2014 May; 26(3):357-62. PubMed ID: 24709976
[TBL] [Abstract][Full Text] [Related]
8. Tumor-busting viruses.
Nettelbeck DM; Curiel DT
Sci Am; 2003 Oct; 289(4):68-75. PubMed ID: 14513520
[No Abstract] [Full Text] [Related]
9. Bystander effects in enzyme/prodrug gene therapy.
Paillard F
Hum Gene Ther; 1997 Oct; 8(15):1733-5. PubMed ID: 9358021
[No Abstract] [Full Text] [Related]
10. Gene therapy for cancers.
Lashford L
Arch Dis Child; 1994 Dec; 71(6):485-7. PubMed ID: 7726604
[No Abstract] [Full Text] [Related]
11. Molecular targets and cancer therapeutics: discovery, biology, and clinical applications. October 29-November 2, 2001. Miami Beach, Florida, USA. Abstracts.
Clin Cancer Res; 2001 Nov; 7 Suppl():3653s-3852s. PubMed ID: 11727717
[No Abstract] [Full Text] [Related]
12. Gut microbes shape response to cancer immunotherapy.
Kaiser J
Science; 2017 Nov; 358(6363):573. PubMed ID: 29097525
[No Abstract] [Full Text] [Related]
13. The evolving landscape of criteria for evaluating tumor response in the era of cancer immunotherapy: From Karnofsky to iRECIST.
Inno A; Lo Russo G; Salgarello M; Corrao G; Casolino R; Galli G; Modena A; Romano L; Pusceddu S; Greco FG; Garassino MC; Gori S
Tumori; 2018; 104(2):88-95. PubMed ID: 29714647
[TBL] [Abstract][Full Text] [Related]
14. [Monoclonal antibodies and chemotherapy: therapeutic indications].
Carrozza F
Suppl Tumori; 2004; 3(4):S127-9. PubMed ID: 15206238
[No Abstract] [Full Text] [Related]
15. Chemotherapy Foundation Symposium XVI. Innovative Cancer Therapy for Tomorrow. New York City, New York, USA. November 11-13, 1998. Abstracts.
Cancer Invest; 1999; 17 Suppl 1():1-98. PubMed ID: 10083854
[No Abstract] [Full Text] [Related]
16. Prodrugs in cancer chemotherapy.
Connors TA; Knox RJ
Stem Cells; 1995 Sep; 13(5):501-11. PubMed ID: 8528099
[TBL] [Abstract][Full Text] [Related]
17. Delivery of molecular medicine to solid tumors.
Jain RK
Science; 1996 Feb; 271(5252):1079-80. PubMed ID: 8599082
[No Abstract] [Full Text] [Related]
18. Potential of Toll-like receptor 9 agonists in combined anticancer immunotherapy strategies: synergy of PAMPs and DAMPs?
Holtick U; Klein-Gonzalez N; von Bergwelt-Baildon MS
Immunotherapy; 2011 Mar; 3(3):301-4. PubMed ID: 21395370
[No Abstract] [Full Text] [Related]
19. Immunotherapy in children: report from the Reisensburg-Symposium October 20-22, 2004 and recent advances.
Klingebiel T; Bader P; Hollatz G; Koehl U; Lehrnbecher T; Meisel R; Dilloo D
Klin Padiatr; 2006; 218(6):355-65. PubMed ID: 17080339
[TBL] [Abstract][Full Text] [Related]
20. Antitumor activities of IL-12 and mechanisms of action.
Shurin MR; Esche C; Péron JM; Lotze MT
Chem Immunol; 1997; 68():153-74. PubMed ID: 9329221
[No Abstract] [Full Text] [Related]
[Next] [New Search]
